NRBO

NeuroBo Pharmaceuticals Stock Price

3.0727
0.0027 (0.09%)
Upgrade to Real-Time
Regular Market
3.0727

Low
2.70

52 Week Range

High
7.6094

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
NeuroBo Pharmaceuticals Inc NRBO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0027 0.09% 3.0727 12:36:54
Open Price Low Price High Price Close Price Prev Close
3.08 2.95 3.15 3.07
Bid Price Ask Price Spread News
3.07 3.09 0.02 1 -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,090 165,963 $ 3.06 $ 507,786 - 2.70 - 7.6094
Last Trade Time Type Quantity Stock Price Currency
12:38:50 1 $ 3.07 USD

Period:

Draw Mode:

NeuroBo Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 68.64M 22.29M 12.26M $ - $ - -1.84 -1.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 16.80%

more financials information »

NeuroBo Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NRBO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.735.632.703.9027,519,4970.342712.55%
1 Month3.315.632.703.897,360,296-0.2373-7.17%
3 Months3.566.572.703.862,651,146-0.4873-13.69%
6 Months5.566.572.704.031,412,053-2.49-44.74%
1 Year7.217.60942.704.12739,647-4.14-57.38%
3 Years9.1530.002.704.38483,355-6.08-66.42%
5 Years9.1530.002.704.38483,355-6.08-66.42%

NeuroBo Pharmaceuticals Description

NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments.


Your Recent History
NASDAQ
NRBO
NeuroBo Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.